Polygenic risk scores across the extended psychosis spectrum

Imagem de Miniatura
Arquivos
art_SMIGIELSKI_Polygenic_risk_scores_across_the_extended_psychosis_spectrum_2021.PDF (2.15 MB)
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGERNATURE
Autores
SMIGIELSKI, Lukasz
PAPIOL, Sergi
THEODORIDOU, Anastasia
HEEKEREN, Karsten
GERSTENBERG, Miriam
WOTRUBA, Diana
BUECHLER, Roman
HOFFMANN, Per
HERMS, Stefan
ADORJAN, Kristina
Citação
TRANSLATIONAL PSYCHIATRY, v.11, n.1, article ID 600, 11p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
As early detection of symptoms in the subclinical to clinical psychosis spectrum may improve health outcomes, knowing the probabilistic susceptibility of developing a disorder could guide mitigation measures and clinical intervention. In this context, polygenic risk scores (PRSs) quantifying the additive effects of multiple common genetic variants hold the potential to predict complex diseases and index severity gradients. PRSs for schizophrenia (SZ) and bipolar disorder (BD) were computed using Bayesian regression and continuous shrinkage priors based on the latest SZ and BD genome-wide association studies (Psychiatric Genomics Consortium, third release). Eight well-phenotyped groups (n = 1580; 56% males) were assessed: control (n = 305), lower (n = 117) and higher (n = 113) schizotypy (both groups of healthy individuals), at-risk for psychosis (n = 120), BD type-I (n = 359), BD type-II (n = 96), schizoaffective disorder (n = 86), and SZ groups (n = 384). PRS differences were investigated for binary traits and the quantitative Positive and Negative Syndrome Scale. Both BD-PRS and SZ-PRS significantly differentiated controls from at-risk and clinical groups (Nagelkerke's pseudo-R-2: 1.3-7.7%), except for BD type-II for SZ-PRS. Out of 28 pairwise comparisons for SZ-PRS and BD-PRS, 9 and 12, respectively, reached the Bonferroni-corrected significance. BD-PRS differed between control and at-risk groups, but not between at-risk and BD type-I groups. There was no difference between controls and schizotypy. SZ-PRSs, but not BD-PRSs, were positively associated with transdiagnostic symptomology. Overall, PRSs support the continuum model across the psychosis spectrum at the genomic level with possible irregularities for schizotypy. The at-risk state demands heightened clinical attention and research addressing symptom course specifiers. Continued efforts are needed to refine the diagnostic and prognostic accuracy of PRSs in mental healthcare.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/44239
Referências
  1. Aas M, 2020, BIPOLAR DISORD, V22, P174, DOI 10.1111/bdi.12851
  2. Alnaes D, 2019, JAMA PSYCHIAT, V76, P739, DOI 10.1001/jamapsychiatry.2019.0257
  3. Amare AT, 2020, MOL PSYCHIATR, DOI 10.1038/s41380-020-0689-5
  4. Aminoff SR, 2015, J AFFECT DISORDERS, V183, P310, DOI 10.1016/j.jad.2015.05.021
  5. Angst J, 2002, SCHIZOPHR RES, V57, P5, DOI 10.1016/S0920-9964(02)00328-6
  6. Angst J, 2005, J AFFECT DISORDERS, V88, P217, DOI 10.1016/j.jad.2005.05.011
  7. Anttila V, 2018, SCIENCE, V360, P1313, DOI 10.1126/science.aap8757
  8. Auton A., 2015, NATURE, V526, DOI [10.1038/nature15393, DOI 10.1038/NATURE15393]
  9. Barrantes-Vidal N, 2015, SCHIZOPHRENIA BULL, V41, pS408, DOI 10.1093/schbul/sbu191
  10. Budde M, 2019, AM J MED GENET B, V180, P89, DOI 10.1002/ajmg.b.32639
  11. Calafato MS, 2018, BRIT J PSYCHIAT, V213, P535, DOI 10.1192/bjp.2018.89
  12. Wald NJ, 2019, GENET MED, V21, P1705, DOI 10.1038/s41436-018-0418-5
  13. Wang DH, 2021, MOL PSYCHIATR, DOI 10.1038/s41380-020-00983-1
  14. Wigman JTW, 2012, ACTA PSYCHIAT SCAND, V126, P266, DOI 10.1111/j.1600-0447.2012.01857.x
  15. Woodberry KA, 2016, HARVARD REV PSYCHIAT, V24, P87, DOI 10.1097/HRP.0000000000000109
  16. Woodberry KA, 2010, SCHIZOPHR RES, V123, P188, DOI 10.1016/j.schres.2010.06.021
  17. Wotruba D, 2014, SCHIZOPHRENIA BULL, V40, P1095, DOI 10.1093/schbul/sbt161
  18. Zhang JP, 2019, AM J PSYCHIAT, V176, P21, DOI 10.1176/appi.ajp.2018.17121363
  19. Zwicker A, 2018, PSYCHOL MED, V48, P1925, DOI 10.1017/S003329171700383X
  20. Cao HY, 2020, MOL PSYCHIATR, DOI 10.1038/s41380-020-0699-3
  21. Cardno AG, 2014, SCHIZOPHRENIA BULL, V40, P504, DOI 10.1093/schbul/sbu016
  22. Charney AW, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2016.242
  23. Collins PY, 2011, NATURE, V475, P27, DOI 10.1038/475027a
  24. Coombes BJ., 2020, TRANSL PSYCHIAT, V10, P1, DOI [10.1101/2020.03.31.20044800, DOI 10.1101/2020.03.31.20044800]
  25. Debbane M, 2015, SCHIZOPHRENIA BULL, V41, pS396, DOI 10.1093/schbul/sbu176
  26. Delaneau O, 2013, NAT METHODS, V10, P5, DOI 10.1038/nmeth.2307
  27. Derks EM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037852
  28. Fernandez-Cruz AL, 2016, NPJ SCHIZOPHR, V2, DOI 10.1038/npjschz.2016.35
  29. Frank J, 2015, MOL PSYCHIATR, V20, P150, DOI 10.1038/mp.2014.56
  30. Fusar-Poli P, 2020, JAMA PSYCHIAT, V77, P755, DOI 10.1001/jamapsychiatry.2019.4779
  31. Fusar-Poli P, 2016, SCHIZOPHRENIA BULL, V42, P1395, DOI 10.1093/schbul/sbw020
  32. Fusar-Poli P, 2013, JAMA PSYCHIAT, V70, P107, DOI 10.1001/jamapsychiatry.2013.269
  33. Fusar-Poli P, 2012, ARCH GEN PSYCHIAT, V69, P220, DOI 10.1001/archgenpsychiatry.2011.1472
  34. Gaebel W, 2020, DIALOGUES CLIN NEURO, V22, P7, DOI 10.31887/DCNS.2020.22.1/wgaebel
  35. Gandal MJ, 2016, NAT NEUROSCI, V19, P1397, DOI 10.1038/nn.4409
  36. Ge T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09718-5
  37. Geoffroy Pierre Alexis, 2013, Front Psychiatry, V4, P136, DOI 10.3389/fpsyt.2013.00136
  38. Gibson G, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008060
  39. Grunblatt E, 2018, J PSYCHIATR RES, V96, P209, DOI 10.1016/j.jpsychires.2017.10.010
  40. Hatzimanolis A, 2018, SCHIZOPHRENIA BULL, V44, P338, DOI 10.1093/schbul/sbx074
  41. Hauser TU, 2017, PSYCHOL MED, V47, P1246, DOI 10.1017/S0033291716003305
  42. Howes OD, 2020, BIOL PSYCHIAT, V88, P304, DOI 10.1016/j.biopsych.2020.03.012
  43. Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
  44. Ikeda M, 2021, J HUM GENET, V66, P53, DOI 10.1038/s10038-020-0814-y
  45. Jonas KG, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0612-5
  46. Jones HJ, 2016, JAMA PSYCHIAT, V73, P221, DOI 10.1001/jamapsychiatry.2015.3058
  47. Kauppi K, 2015, SCHIZOPHRENIA BULL, V41, P736, DOI 10.1093/schbul/sbu152
  48. Kaur T, 2010, CURR TOP BEHAV NEURO, V4, P97, DOI 10.1007/7854_2010_56
  49. Kavanagh DH, 2015, MOL PSYCHIATR, V20, P72, DOI 10.1038/mp.2014.148
  50. KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261
  51. Kendler KS, 2016, JAMA PSYCHIAT, V73, P193, DOI 10.1001/jamapsychiatry.2015.2964
  52. Koenker R., 2017, HDB QUANTILE REGRESS
  53. Kuhn S, 2012, J PSYCHIATR RES, V46, P960, DOI 10.1016/j.jpsychires.2012.04.007
  54. Le Cook Benjamin, 2013, Shanghai Arch Psychiatry, V25, P55, DOI 10.3969/j.issn.1002-0829.2013.01.011
  55. Lichtenstein P, 2009, LANCET, V373, P234, DOI 10.1016/S0140-6736(09)60072-6
  56. Markota M, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0242-3
  57. Martin AR, 2019, NAT GENET, V51, P584, DOI 10.1038/s41588-019-0379-x
  58. McGlashan TH, 2001, STRUCTURED INTERVIEW
  59. Meller T, 2019, SCHIZOPHR RES, V208, P67, DOI 10.1016/j.schres.2019.04.018
  60. Mohr C, 2015, SCHIZOPHRENIA BULL, V41, pS436, DOI 10.1093/schbul/sbu185
  61. Mullins N, 2021, NAT GENET, V53, P817, DOI 10.1038/s41588-021-00857-4
  62. Muntane G, 2021, HUM GENET, V140, P441, DOI 10.1007/s00439-020-02213-8
  63. Murphy J, 2012, SCHIZOPHRENIA BULL, V38, P360, DOI 10.1093/schbul/sbq092
  64. Musliner KL, 2020, AM J PSYCHIAT, V177, P936, DOI 10.1176/appi.ajp.2020.19111195
  65. Narrow WE, 2011, J MENT HEALTH POLICY, V14, P197
  66. Nelemans SA, 2021, J YOUTH ADOLESCENCE, V50, P159, DOI 10.1007/s10964-020-01353-4
  67. Nenadic Igor, 2020, Psychol Med, P1, DOI 10.1017/S0033291720002822
  68. Ni GY, 2021, BIOL PSYCHIAT, V90, P611, DOI 10.1016/j.biopsych.2021.04.018
  69. Oestreich LKL, 2015, INT J PSYCHOPHYSIOL, V97, P131, DOI 10.1016/j.ijpsycho.2015.05.014
  70. Oliver D, 2020, SCHIZOPHRENIA BULL, V46, P110, DOI 10.1093/schbul/sbz039
  71. Oliver D, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00174
  72. Pain O, 2018, AM J MED GENET B, V177, P416, DOI 10.1002/ajmg.b.32630
  73. Palk AC, 2019, PHILOS ETHICS HUM ME, V14, DOI 10.1186/s13010-019-0073-8
  74. Penttila M, 2014, BRIT J PSYCHIAT, V205, P88, DOI 10.1192/bjp.bp.113.127753
  75. Pepper E, 2014, CURR PSYCHIATRY REV, V10, P133, DOI 10.2174/1573400510666140319235545
  76. Perkins DO, 2020, AM J PSYCHIAT, V177, P155, DOI 10.1176/appi.ajp.2019.18060721
  77. Polson NG., 2010, BAYESIAN STAT, V9, P105
  78. Radua J, 2018, WORLD PSYCHIATRY, V17, P49, DOI 10.1002/wps.20490
  79. RAINE A, 1991, SCHIZOPHRENIA BULL, V17, P555, DOI 10.1093/schbul/17.4.555
  80. Richards AL, 2020, SCHIZOPHRENIA BULL, V46, P336, DOI 10.1093/schbul/sbz061
  81. Riglin L, 2017, LANCET PSYCHIAT, V4, P57, DOI 10.1016/S2215-0366(16)30406-0
  82. Ripke S., 2020, MAPPING GENOMIC LOCI, DOI [10.1101/2020.09.12.20192922, DOI 10.1101/2020.09.12.20192922, 10.1101/20 20.09.12.20192922]
  83. Santoro ML, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0230-7
  84. Schultze-Lutter F, 2015, EUR PSYCHIAT, V30, P405, DOI 10.1016/j.eurpsy.2015.01.010
  85. Schultze-Lutter F, 2010, SCHIZOPHRENIA PRONEN
  86. Schultze-Lutter F, 2007, SCHIZOPHRENIA PRONEN
  87. Schultze-Lutter F, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00476
  88. Seidman LJ, 2016, JAMA PSYCHIAT, V73, P1239, DOI 10.1001/jamapsychiatry.2016.2479
  89. Sengupta SM, 2017, SCHIZOPHR RES, V184, P116, DOI 10.1016/j.schres.2016.11.039
  90. Shafee R, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0124-8
  91. Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
  92. Sieradzka D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094398
  93. Singh J, 2012, HANDB EXP PHARMACOL, V212, P187, DOI 10.1007/978-3-642-25761-2_8
  94. Smelan OB, 2020, MOL PSYCHIATR, V25, P844, DOI 10.1038/s41380-018-0332-x
  95. Smigielski L, 2021, SCHIZOPHRENIA BULL, V47, P1495, DOI 10.1093/schbul/sbab034
  96. Smith TJ., 2013, MULTIPLE LINEAR REGR, V39, P17, DOI 10.1201/9780429066665-6
  97. Stefanis NC, 2007, BIOL PSYCHIAT, V62, P784, DOI 10.1016/j.biopsych.2006.11.015
  98. Strain E, 2009, KAPLAN SADOCKS COMPR
  99. Tesli M, 2014, ACTA PSYCHIAT SCAND, V130, P311, DOI 10.1111/acps.12307
  100. Theodoridou A, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00166
  101. Torkamani A, 2018, NAT REV GENET, V19, P581, DOI 10.1038/s41576-018-0018-x
  102. Unterrassner L, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00775
  103. van Os J, 2009, PSYCHOL MED, V39, P179, DOI 10.1017/S0033291708003814
  104. Vassos E, 2017, BIOL PSYCHIAT, V81, P470, DOI 10.1016/j.biopsych.2016.06.028

Coleções
Artigos e Materiais de Revistas Científicas - LIM/27